On Friday, VMware, Inc. (NYSE:VMW)’s shares surged 1.68% to $83.38, after VMware declared the continued expansion of VMware vCloud® Air™ with the general availability of service in Australia.
Complementing VMware’s vCloud Air Network of service providers, the new VMware-operated location provides customers with a local Asia Pacific Infrastructure as a Service that can assist address local compliance and data locality concerns. This initial VMware vCloud Air deployment in Australia is hosted out of a Telstra connected data center.
VMware vCloud Air integrates seamlessly with current IT infrastructures to make it easy to extend existing applications and integrate them with new transformational cloud-native applications. vCloud Air offers virtual private, dedicated and disaster recovery that works with the applications businesses run recently, offering greater agility and availability on a secure foundation of VMware vSphere®. IT departments can view, manage and operate this cloud environment using the VMware vSphere platform that they already know, and it is compatible with Hybrid Cloud Powered Services offered by the VMware vCloud Air Network of service providers. The new VMware vCloud Air location in Australia will enable customers the ability to have their data stored under Australian compliance and data protection regulations.
VMware, Inc. provides virtualization infrastructure solutions in the United States and internationally. The company’s virtualization infrastructure solutions comprise a suite of products designed to deliver a software-defined data center (SDDC), run on industry-standard desktop computers and servers, and support a range of operating system and application environments, in addition to networking and storage infrastructures.
Edwards Lifesciences Corp. (NYSE:EW)’s shares gained 1.66% to $141.68, during the last trading session on Friday, as Edwards Lifesciences plans to declare its operating results for the quarter ended March 31, 2015 after the market closes on Thursday, April 23, 2015, and will host a conference call at 5:00 p.m. ET that day to talk about those results.
Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. The company offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and their delivery systems for the nonsurgical replacement of heart valves.
At the end of Friday’s trade, Insulet Corporation (NASDAQ:PODD)’s shares gained 1.63% to $30.49, as Insulet plans to release its financial results for the first quarter of 2015 on April 30, 2015 after the close of the financial markets. In connection with the release, administration will host a conference call that day at 4:30 p.m. (Eastern Time). Material information may be discussed on the call concerning the Company, its operations, strategies and prospects.
Insulet Corporation develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the United States. The company offers OmniPod Insulin Administration System (OmniPod System), which comprises of the OmniPod, a disposable insulin infusion device that integrates an infusion set, automated cannula insertion, insulin reservoir, drive mechanism, and batteries; and personal diabetes manager, a handheld wireless device.
Finally, AmerisourceBergen Corporation (NYSE:ABC), ended its Friday’s trading session with 1.63% gain, and closed at $115.35, hitting its highest level, as AmerisourceBergen Corporation declared that it plans to release its results for the Second Quarter Fiscal 2015 on Thursday, April 30, 2015 preceding to the opening of trading on the New York Stock Exchange. The Company will host a conference call to talk about the results at 11:00 a.m. Eastern Time on April 30, 2015.
Participating in the conference call will be:
- Steven H. Collis, President & Chief Executive Officer
- Tim G. Guttman, Executive Vice President & Chief Financial Officer
AmerisourceBergen Corporation sources and distributes pharmaceutical products to healthcare providers, pharmaceutical and biotech manufacturers, and specialty drug patients in the United States and internationally.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
